HIV-1 anchor inhibitors and membrane fusion inhibitors target distinct but overlapping steps in virus entry

HIV-1 entry into cells is mediated by the envelope glycoprotein (Env) and represents an attractive target for therapeutic intervention. Two drugs that inhibit HIV entry are approved for clinical use: the membrane fusion-inhibitor T20 (Fuzeon, enfuvirtide) and the C-C chemokine receptor type 5 (CCR5)...

Descripción completa

Detalles Bibliográficos
Autores principales: Eggink, Dirk, Bontjer, Ilja, de Taeye, Steven W., Langedijk, Johannes P. M., Berkhout, Ben, Sanders, Rogier W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Biochemistry and Molecular Biology 2019
Materias:
Microbiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463712/
https://www.ncbi.nlm.nih.gov/pubmed/30696772
http://dx.doi.org/10.1074/jbc.RA119.007360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6463712/
https://www.ncbi.nlm.nih.gov/pubmed/30696772
http://dx.doi.org/10.1074/jbc.RA119.007360

Ejemplares similares